Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 12

1.

PET of HER2-positive pulmonary metastases with 18F-ZHER2:342 affibody in a murine model of breast cancer: comparison with 18F-FDG.

Kramer-Marek G, Bernardo M, Kiesewetter DO, Bagci U, Kuban M, Aras O, Zielinski R, Seidel J, Choyke P, Capala J.

J Nucl Med. 2012 Jun;53(6):939-46. doi: 10.2967/jnumed.111.100354. Erratum in: J Nucl Med. 2012 Jul;53(7):1169. Omer, Aras [corrected to Aras, Omer].

2.

Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model.

Kramer-Marek G, Gijsen M, Kiesewetter DO, Bennett R, Roxanis I, Zielinski R, Kong A, Capala J.

J Nucl Med. 2012 Apr;53(4):629-37. doi: 10.2967/jnumed.111.096685.

3.

Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with (99m)Tc, (111)In, and (125)I.

Hofstrom C, Orlova A, Altai M, Wangsell F, Graslund T, Tolmachev V.

J Med Chem. 2011 Jun 9;54(11):3817-26. doi: 10.1021/jm200065e.

PMID:
21524142
4.

HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [⁹⁹(m)Tc(CO)₃](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation.

Tolmachev V, Hofström C, Malmberg J, Ahlgren S, Hosseinimehr SJ, Sandström M, Abrahmsén L, Orlova A, Gräslund T.

Bioconjug Chem. 2010 Nov 17;21(11):2013-22. doi: 10.1021/bc1002357.

PMID:
20964447
6.

Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications.

Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Ståhl S, Frejd FY.

FEBS Lett. 2010 Jun 18;584(12):2670-80. doi: 10.1016/j.febslet.2010.04.014. Review.

7.

Design of an optimized scaffold for affibody molecules.

Feldwisch J, Tolmachev V, Lendel C, Herne N, Sjöberg A, Larsson B, Rosik D, Lindqvist E, Fant G, Höidén-Guthenberg I, Galli J, Jonasson P, Abrahmsén L.

J Mol Biol. 2010 Apr 30;398(2):232-47. doi: 10.1016/j.jmb.2010.03.002.

PMID:
20226194
8.

Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.

Ahlgren S, Wållberg H, Tran TA, Widström C, Hjertman M, Abrahmsén L, Berndorff D, Dinkelborg LM, Cyr JE, Feldwisch J, Orlova A, Tolmachev V.

J Nucl Med. 2009 May;50(5):781-9. doi: 10.2967/jnumed.108.056929.

9.

Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules.

Ekblad T, Orlova A, Feldwisch J, Wennborg A, Karlström AE, Tolmachev V.

Bioorg Med Chem Lett. 2009 Jul 15;19(14):3912-4. doi: 10.1016/j.bmcl.2009.03.083.

PMID:
19364646
10.

Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry.

Tolmachev V, Friedman M, Sandström M, Eriksson TL, Rosik D, Hodik M, Ståhl S, Frejd FY, Orlova A.

J Nucl Med. 2009 Feb;50(2):274-83. doi: 10.2967/jnumed.108.055525.

11.

Tumor imaging using a picomolar affinity HER2 binding affibody molecule.

Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Höidén-Guthenberg I, Widström C, Carlsson J, Tolmachev V, Ståhl S, Nilsson FY.

Cancer Res. 2006 Apr 15;66(8):4339-48.

12.

Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.

Orlova A, Nilsson FY, Wikman M, Widström C, Ståhl S, Carlsson J, Tolmachev V.

J Nucl Med. 2006 Mar;47(3):512-9.

Supplemental Content

Support Center